BioAge IPO

bioagelabs.com

BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.

Founded2015
Total Funding to Date$132.86MM
Register for Details

For more details on financing and valuation for BioAge, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

BioAge Ticker Symbol

BioAge does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

BioAge Stock Price

The stock price for BioAge will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

BioAge Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
12/3/2020 Series C $270.78MM $XXX.XX $XXX.XX
1/24/2019 Series B $86.05MM $XXX.XX $XXX.XX
7/28/2017 Series A-1, A-2, A-3, and A-4 $43.84MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like BioAge in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B